Market reaction to a report that cells edited with CRISPR technology can activate a cancer-causing gene has been severe for companies developing CRISPR-based therapies. But, the nascent industry has faced and survived such challenges before. Meanwhile, new tools are making gene therapies faster, easier and more accessible than ever, and lowering the industry’s barriers to entry.
To read this Market Insight, you’ll need to sign in
If you don’t have a subscription, sign up or start a free trial .